Lung Transplant Clinical Trials

Clinical trials related to Lung Transplant Procedure

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Lung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount an immune response against them. This is called rejection. But not everyone who has a transplant develops DSA, and not everyone who has DSA develops rejection. Researchers want to understand why.

Objective: To collect data to try to find out why some people develop rejection after lung transplants while others do not.

Eligibility: People aged 18 to 75 years who have progressive lung disease or undergone or may undergo a lung transplant.

Design: Participants will have clinic visits every 3 to 6 months for up to 4 years. Some visits might require an overnight stay. Each visit will include multiple tests and procedures: Physical exam with blood and urine tests. Some blood will be used for genetic testing. Imaging scans. Participants will have 2 types of scan to get images of their lungs. For one, they will have a contrast agent given through a tube inserted into a vein. Six-minute walk test. Participants will walk back and forth in a hallway at their own pace. Researchers will check on how their body responds. Lung function test. Participants will breathe into a tube connected to a machine. Two other tests are optional: Bronchoscopy with washings (lavage). A long tube with a light will be threaded down through the participant s nose or mouth and into their lungs. Endomicroscopy. During the bronchoscopy a tiny camera may be used to take pictures inside the lungs. ...

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

⁃ In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Stated willingness to comply with study procedures and availability for the duration of the study.

• Male or female, aged 18 - 75 years of age.

• Have progressive lung disease or undergone or being evaluated for lung transplantation.

• Ability of subjects to understand the informed consent document.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Andrew G Keel, C.R.N.P.
andrew.keel@nih.gov
(301) 648-5674
Backup
Muhtadi H Alnababteh, M.D.
muhtadi.alnababteh@nih.gov
(301) 827-3272
Time Frame
Start Date: 2026-05-11
Estimated Completion Date: 2032-03-27
Participants
Target number of participants: 100
Treatments
DSA-
Lung transplant patients who didn't develop donor specific antibodies
DSA+
Lung transplant patients who developed donor specific antibodies
Related Therapeutic Areas
Sponsors
Leads: National Heart, Lung, and Blood Institute (NHLBI)
Collaborators: National Institutes of Health Clinical Center (CC)

This content was sourced from clinicaltrials.gov